Canada markets closed

Plantable Health Inc. (PLBL.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.0100+0.0050 (+100.00%)
At close: 09:46AM EST
Full screen
Previous Close0.0050
Open0.0050
Bid0.0050 x N/A
Ask0.0100 x N/A
Day's Range0.0050 - 0.0050
52 Week Range0.0050 - 0.4400
Volume66,000
Avg. Volume147,009
Market Cap632,500
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Plantable Health Inc. Reports Third Quarter Financial Results

    New York, New York--(Newsfile Corp. - November 10, 2022) - Plantable Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), provides a clinically proven dietary intervention program to reverse and prevent chronic disease, today reported the financial results for the third quarter ended September 30, 2022. "Food as Medicine is now here. The recent White House announcement of their support of insurance coverage for dietary lifestyle interventions, including Food as Medicine, paves

  • Newsfile

    Plantable Health Announces U.S. Distribution Partnership with CookUnity, Bringing Plantable's Nutrient Dense Meals to a Wider Audience

    New York, New York--(Newsfile Corp. - October 25, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces it has entered into a new distribution agreement with CookUnity, a Brooklyn-based chef-to-eater marketplace, to distribute Plantable's fresh meals across the East Coast, with future expansion to the rest of the United States. This agreement represents a significant milestone for Plantable. CookUnity is the first chef-to-eater meal subscription

  • Newsfile

    Plantable Health Announces the Opening of a New Multi-Center Clinical Trial with Memorial Sloan Kettering Cancer Center

    New York, New York--(Newsfile Corp. - October 18, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces the opening of a new Clinical Trial, NUTRIVENTION-3, at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York with Dr. Urvi Shah as Principal Investigator. This trial follows on the back of the promising recently presented preliminary results for NUTRIVENTION study (NCT04920084). The primary objective for this trial is ...